Transport of new non-cross-resistant antitumor compounds of the benzoperimidine family in multidrug resistant cells

European Journal of Pharmacology

Volumn 413, Issue 2-3, 2001, Pages 131-141

  Tkaczyk Gobis, Katarzyna ^a   Tarasiuk, Jolanta ^a   Seksek, Olivier ^b   Stefanska, Barbara ^a   Borowski, Edward ^a   Garnier Suillerot, Arlette ^b  

^a GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

^b UNIVERSITÉ PARIS 13   (France)

Author keywords

Benzoperimidine; MRP1 (multidrug resistance associated protein); Multidrug resistance; P glycoprotein

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BENZOPERIMIDINE 1; BENZOPERIMIDINE 2; BENZOPERIMIDINE 3; BENZOPERIMIDINE DERIVATIVE; CYTOTOXIC AGENT; DNA; DOXORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; PIRARUBICIN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MEMBRANE TRANSPORT; CELL NUCLEUS; CELL STRAIN 3T3; CELL STRAIN K 562; CONTROLLED STUDY; CROSS RESISTANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG RELEASE; DRUG UPTAKE; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; LYSOSOME; MAMMAL CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSPORT KINETICS;

3T3 CELLS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CELL NUCLEUS; DNA; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG SCREENING ASSAYS, ANTITUMOR; GENES, MDR; HUMANS; K562 CELLS; LYSOSOMES; MICE; P-GLYCOPROTEIN; QUINAZOLINES;

EID: 0035895564     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(01)00728-2     Document Type: Article

References (41)

1. The role of idarubicin in adult acute lymphoblastic leukaemia: From drug resistance studies to clinical application
2. Novel multidrug resistance reversal agents
3. P-glycoprotein-mediated efflux of hydroxyrubicin, a neutral anthracycline derivative, in resistant K562 cells
4. New physiological functions for drug-transporting P-glycoproteins?
5. Mechanism of multidrug resistance
6. The impact of transport-associated resistance in anticancer chemotherapy
7. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells
8. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells
9. Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein
10. Determination of the osmotic active drug concentration in the cytoplasm of anthracycline-resistant and -sensitive K562 cells
11. Comparison of the membrane transport of anthracycline derivatives in drug-resistant and drug-sensitive K562 cells
12. Impaired accumulation of drug in multidrug resistant cells. What are the respective contributions of the kinetics of uptake and of P-glycoprotein-mediated efflux of drug?
13. Biochemistry of multidrug resistance mediated by the multidrug transporter
14. Lipophilic cations - A group of model substrates for the multidrug-resistance transporter
15. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines
16. Pirarubicin might partly circumvent the P-glycoprotein-mediated drug resistance of human breast cancer tissues
17. Kinetic parameters for reversal of the multidrug pump as measured for drug accumulation and cell killing
18. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates
19. Biology of the multidrug resistance-associated protein
20. The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depend on the kinetics of their uptake
21. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells
22. Rapid recovery of a functional MDR phenotype caused by MRP after a transient exposure to MDR drugs in a revertant human lung cancer cell line
23. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells
24. Correlation between the kinetics of anthracycline uptake and the resistance factor in cancer cells expressing the multidrug resistance protein or the P-glycoprotein
25. Molecular trapping of a fluorescent ceramide analogue at the Golgi apparatus of fixed cells: Interaction with endogenous lipids provides a trans-Golgi marker for both light and electron microscopy
26. Correlation between the short-term measurements of drug accumulation in living cells and the long-term growth inhibition
27. Mechanism of action-governed design of anthracycline antibiotics: A "turn-off/turn-on" approach
28. The P-glycoprotein efflux pump: How does it transport drugs?
29. Modulation of multidrug resistance - At the threshold
30. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
31. 8,11-dihydroxy-6-[(aminoalkyl)amino-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: Synthesis and antitumor evaluation
32. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal
33. Reversal of multidrug-associated protein-mediated drug resistance by the pyridine analog PAK-104P
34. Microspectrofluorometric study of the kinetics of cellular uptake and metabolization of benzo (a) pyrene in human T47D mammary tumor cells: Evidence for cytochrome P-450 induction
35. Anthracycline incorporation in human lymphocytes: Kinetics of uptake and nuclear concentration
36. Design, synthesis, and in vitro activity of catamphilic reverters of multidrug resistance (MDR). The discovery of a selective, highly efficacious chemosensitizer with potency in the nanomolar range
37. 99mTc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes
38. PSC833, cyclosporin A, and dexniguldipine effects on cellular retention and inhibition of the multidrug resistance pump in human leukemic lymphoblasts
39. Inhibition of the multidrug resistance efflux pump
40. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump
41. Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line